J Breast Cancer.
2023 Feb;26(1):86-91. 10.4048/jbc.2022.25.e50.
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly
- Affiliations
-
- 1Retired Professor, Department of Medicine/Oncology Division, Wake Forest University School of Medicine, One Medical Center Blvd, Winston-Salem, USA
- KMID: 2540048
- DOI: http://doi.org/10.4048/jbc.2022.25.e50
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
- Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
- Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
- Updated Bayesian Network MetaAnalysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer
- Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer
